Since 2022, Oncode Institute and Cancer Research Horizons - the innovation engine of Cancer Research UK - have formed a strategic alliance to accelerate the translation of cancer research into real patient benefits. By combining expertise across borders, we aim to amplify the impact of scientific discoveries and bring new cancer treatments and diagnostics to patients more quickly.  

Shared Vision, Complementary Strengths 

Both organisations are committed to scientific excellence, open collaboration, and patient-centred innovation. Oncode Institute offers a unique translational ecosystem embedded in the Dutch academic landscape, while Cancer Research Horizons brings deep expertise in drug discovery, venture creation, and commercialization at scale. 

Through this alliance, we: 

• Share knowledge, best practices, and innovation strategies
• Explore joint opportunities in drug discovery and development
• Strengthen translational support for academic researchers
• Offer jointly organized training programs, workshops and thematic seminars for researchers and translational professionals
• Expand networks across the UK, the Netherlands, and beyond
• Promote international valorization of cancer research 

A Platform for Cross-Border Innovation 

This partnership creates a platform for shared learning and co-creation. By aligning approaches to early-stage development and commercialisation, we increase the likelihood that promising academic innovations will reach patients—whether through licensing, venture building, or partnerships with industry. 

Our strategic alliance with Cancer Research Horizons reflects our belief that meaningful progress in cancer care / outsmarting cancer requires both national excellence and international collaboration.